Core Insights - Vertiv Holdings Co (NYSE:VRT) stock increased by 16.4% to $83.60 following better-than-expected first-quarter earnings and revenue, along with an upward revision of full-year sales guidance, driven by strong demand for data center infrastructure to support artificial intelligence (AI) [1] Group 1: Stock Performance - The stock is currently trading at its highest level since late March, although it remains 48% below its record high of $155.81 from January 24, and has a year-to-date deficit of 24% [2] - Shares are testing their 50-day moving average, which has not been cleared on a closing basis since a late January bear gap [2] Group 2: Options Activity - Vertiv stock has experienced significant options activity with 28,000 calls and 9,992 puts traded, which is triple the typical overall options volume for this time [3] - The most popular option is the weekly 4/25 90-strike call, with new positions being opened [3] Group 3: Sentiment Shift - There has been a notable shift in trader sentiment, as puts were more popular prior to the recent surge in call activity, indicated by a 10-day put/call volume ratio of 1.05, ranking higher than 95% of readings from the past year [4]

Company Performance - Masco Corporation (MAS) reported adjusted earnings per share (EPS) of 87 cents, missing the Zacks Consensus Estimate of 92 cents by 5.4%, and down from 93 cents in the prior-year quarter [4] - Net sales were $1.8 billion, falling short of the consensus mark of $1.84 billion by 1.9% and declining 6% year over year; excluding divestitures, net sales decreased 3% in local currency [4] - The adjusted operating margin contracted 60 basis points year over year to 18.5%, with adjusted EBITDA at $245 million compared to $255 million in the prior-year quarter [7] Segment Analysis - Plumbing Products segment net sales declined 1% year over year to $1.18 billion, with North American sales up 2% and international sales flat in local currency [6] - Decorative Architectural Products segment reported sales of $617 million, down 16% from the prior-year period; total paint sales decreased in mid-single digits, while PRO paint sales increased in the mid-single digits [8] Financial Position - As of March 31, 2025, Masco had total liquidity of $1.246 billion, down from $1.31 billion a year earlier, with cash and cash investments of $377 million and long-term debt of $2.95 billion [13] - The company repurchased 1.8 million shares for about $130 million and returned $66 million to shareholders in dividends during the reported period [13] Market Environment - The disappointing performance is attributed to a challenging macroeconomic and geopolitical environment, including new tariffs; Masco is implementing pricing adjustments and cost-saving initiatives to address rising cost pressures [2] - Management has refrained from providing full-year 2025 financial guidance due to ongoing uncertainty regarding external developments affecting industry demand and pricing dynamics [3]

Core Viewpoint - Enlight Renewable Energy Ltd. (ENLT) shows potential for upside with a mean price target of $20.40, indicating a 27.8% increase from the current price of $15.96 [1] Price Targets and Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.30, suggesting variability among analysts [2] - The lowest estimate of $18 indicates a 12.8% increase, while the highest estimate suggests a 44.1% surge to $23 [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about ENLT's earnings prospects, with a positive trend in earnings estimate revisions [11] - The Zacks Consensus Estimate for the current year has increased by 0.4% due to one upward revision [12] - ENLT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Knightscope, Inc. (KSCP) has shown a significant price increase of 24.4% over the past four weeks, with a mean price target of $17.67 indicating a potential upside of 250.6% from the current price of $5.04 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $12.50, where the lowest estimate of $9 suggests a 78.6% increase, and the highest estimate of $32 indicates a potential surge of 534.9% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Analyst Sentiment and Earnings Estimates - Analysts have shown increasing optimism about KSCP's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 6.9% rise in the Zacks Consensus Estimate for the current year [12] - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13]

Group 1 - Sunrun (RUN) closed at $6.88, with a 4.9% gain over the past four weeks, and a mean price target of $14.18 indicating a 106.1% upside potential [1] - The mean estimate consists of 24 short-term price targets with a standard deviation of $7.24, where the lowest estimate is $6 (12.8% decline) and the highest is $38 (452.3% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price increases [11][12] Group 2 - RUN has a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - The Zacks Consensus Estimate for the current year has increased by 3.8% due to two upward revisions and one downward revision in estimates [12] - While the consensus price target may not be reliable for predicting the exact gain, it provides a directional guide for potential price movement [13]

Core Viewpoint - Coya Therapeutics, Inc. (COYA) shows significant upside potential with a mean price target of $16.25, indicating a 144.7% increase from its current price of $6.64 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.06, suggesting variability among analysts; the lowest estimate of $14 indicates an 110.8% increase, while the highest target is $18, representing a 171.1% increase [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about COYA's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 7.8% rise in the Zacks Consensus Estimate for the current year [12] - COYA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Group 1 - Middlefield Global Dividend Growers ETF (TSX: MDIV) announced distributions for Q2 2025, with a consistent distribution of $0.06 per trust unit for each of the three months [1] - The record and payable dates for the distributions are April 30, May 31, and June 30, 2025, with corresponding payable dates of May 15, June 13, and July 15, 2025 [1] - The trust units of the Fund trade on the Toronto Stock Exchange under the symbol MDIV [2] Group 2 - The Fund offers a distribution reinvestment plan (DRIP) that allows unitholders to automatically reinvest distributions without commission, facilitating compound growth [2] - Middlefield, founded in 1979, is a specialist equity income asset manager with a focus on high-quality global companies across various sectors [3] - The company provides a range of dividend-focused investment strategies, including ETFs, Mutual Funds, Closed-End Funds, Split-Share Funds, and Flow-through LPs [3]

BSX's Q1 Revenues by Regions Boston Scientific Corporation (BSX) posted first-quarter 2025 adjusted earnings per share (EPS) of 75 cents, up 33.9% from the year-ago figure. The figure beat the Zacks Consensus Estimate by 11.9% and also exceeded the company's adjusted earnings per share guidance range of 66-68 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar). The quarter's adjustments included certain amortization expenses, acquisition/divestitures-related net charges ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. For value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discount ...

- The U.S. Securities and Exchange Commission (“SEC”) has declared effective the post-effective amendment to the registration statement on Form F-4 (File No. 333-283650) (as amended, the “Registration Statement”) filed by Namib Minerals and co-registrant Greenstone Corporation (“Greenstone”) - - Special meeting of stockholders of Hennessy Capital Investment Corp. VI (NASDAQ: HCVI) (“HCVI”) to approve proposed business combination with Namib Minerals and Greenstone (the “Business Combination”) to be held on ...